Latest Share Purchase Plan News

Mayfield Group Holdings Ltd has reported a striking 52.8% increase in revenue and a 127.6% jump in profit for the half-year ending December 2025, driven by manufacturing growth and strategic acquisitions.

Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.

HighCom Limited has revealed a sharp downturn in its half-year results, with revenue plunging 59% and a $6.8 million loss after tax, driven by US government shutdown impacts. The company is banking on new lightweight XTclave® armour products to fuel a recovery in the second half of FY26.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Lynas Rare Earths Ltd has reported a striking half-year turnaround with a 1260% surge in net profit, underpinned by rising rare earth prices and strategic expansions. The company also completed a major equity raise to fuel its ambitious Towards 2030 growth plan.

Horizon Minerals has launched a Share Purchase Plan allowing eligible shareholders in Australia and New Zealand to buy additional shares between $2,000 and $30,000. The offer runs until 10 March 2026, with potential early closure depending on demand.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

Rox Resources is advancing rapidly toward ore production at its Youanmi Gold Project, with underground mining progress, drilling programs underway, and critical plant construction contracts secured.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

Aeris Resources has reported a robust half-year performance with a 62% jump in profit, a successful $101.6 million equity raise, and a strategic divestment of North Queensland assets. The company also announced plans to acquire Peel Mining’s South Cobar Copper Project, signaling an aggressive growth trajectory.